Real World Study of VIEKIRAX (ombitasvir/paritaprevir/ritonavir) and EXVIERA (dasabuvir) With Or Without Ribavirin In Patients With Chronic Hepatitis C Virus Infection.
Phase of Trial: Phase III
Latest Information Update: 14 Apr 2018
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Acronyms AMBER
- 14 Apr 2018 According to results presented at The International Liver Congress 2018, this first real world experience study was carried-out in 2014-2015.
- 14 Apr 2018 Results (n=202) of an analysis of two years follow-up focusing on risk of hepatocellur carcinoma development, presented at The International Liver Congress 2018.
- 24 Oct 2017 Results presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases.